一种治疗性小分子增强了g-振荡,并改善了阿尔茨海默病模型小鼠的认知/记忆
Xiaofei Wei1,2, Jesus J Campagna3, Barbara Jagodzinska3
1Department of Neurology, The David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095.
概括
一种新药,DLL-920,可以刺激大脑.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 认知科学 认知科学
背景情况:
- 大脑节律,特别是马振荡 (γ-振荡),对于工作记忆等认知功能至关重要.
- 减少的g-振荡与神经系统疾病有关,包括早期阿尔茨海默病 (AD).
研究的目的:
- 研究一种新型小分子DDL-920的治疗潜力,用于改善阿尔茨海默病的认知缺陷.
- 阐明DLL-920在调节大脑节律和增强认知功能的作用机制.
主要方法:
- 在AD的小鼠模型中利用了解剖学,体外和体外电生理学和行为分析.
- 研究了DLL-920作为特定GABA A受体的负调节器的影响.
- 使用巴恩斯迷宫评估认知和记忆的改善.
主要成果:
- DDL-920是一种大脑透的小分子,被发现增加了g-振荡.
- 口服DDL-920改善了AD模型小鼠的认知和记忆障碍.
- 该分子选择性调节含有α1β2δ子单元的GABA A受体,影响表达parvalbumin的内部神经元.
结论:
- 通过恢复认知功能,DDL-920显示出作为阿尔茨海默病治疗剂的前景.
- 该药物通过抑制性内部神经元的调制来增强内源性γ振荡,提供一种依赖状态的认知增强方法.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
112
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
112
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171


